Peter Attia MD407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more
At a glance
WHAT IT’S REALLY ABOUT
Obicetrapib and CETP inhibition: early LDL lowering plus Alzheimer’s potential
- Michael Davidson describes a prevention-first approach to ASCVD that prioritizes early, lifetime LDL lowering over short-term (10-year) risk estimates, arguing plaque is easier to prevent than reverse.
- The episode traces the rise and fall of CETP inhibitors—initially pursued for HDL raising—showing how torcetrapib failed from off-target toxicity and how later evidence (Mendelian randomization and REVEAL) clarified that outcome benefits track with LDL/non-HDL lowering.
- Obicetrapib is presented as a next-generation, high-potency oral CETP inhibitor with substantial LDL-C reduction, notable Lp(a) lowering, and ongoing phase 3/outcomes programs (including PREVAIL) aimed at global approval.
- A major theme is whether obicetrapib could help prevent Alzheimer’s disease, especially in APOE4 carriers, based on CETP/APOE genetics, brain cholesterol transport biology, animal data, and early biomarker results such as p-tau217 shifts.
- The conversation also covers pragmatic barriers—drug pricing and PBM access, trial design limitations, and the need for better biomarkers/AI-enabled trial reform—plus a nuanced view of omega-3 trials and DHA brain delivery challenges.
IDEAS WORTH REMEMBERING
5 ideasReframe prevention around lifetime LDL exposure, not short-term risk.
Davidson argues ASCVD prevention should target causal drivers (especially LDL/apoB-containing particles) rather than 10-year risk calculators that underestimate lifetime exposure in younger adults. He uses an “8-gram lifetime LDL exposure” heuristic to explain why keeping LDL <~80 mg/dL across decades could largely prevent disease.
CETP inhibition’s cardiovascular value is about LDL lowering, not HDL raising.
Early CETP inhibitor programs were designed to raise HDL (thought to be protective), but outcomes repeatedly failed until evidence clarified that benefits track with LDL/non-HDL lowering—not HDL raising. Mendelian randomization and the Merck REVEAL trial helped “rescue” CETP inhibition by showing event reduction consistent with achieved LDL lowering.
CETP is a viable target; the problem was specific drugs and trial execution.
Torcetrapib increased mortality due to off-target adrenal/aldosterone effects (including blood pressure increases), demonstrating that mechanism-target validity can be undermined by molecule-specific toxicity. Subsequent CETP inhibitors largely avoided this off-target issue but still varied in potency, trial design, and commercial feasibility (e.g., anacetrapib’s fat deposition and extremely long washout).
Obicetrapib is positioned as a potent oral add-on that could simplify post-statin therapy—pending PREVAIL outcomes.
Obicetrapib (10 mg) is presented as a more potent CETP inhibitor: ~40–50% LDL-C lowering as monotherapy, stronger effects when combined with ezetimibe, and meaningful add-on LDL lowering in well-treated FH and ASCVD populations. NewAmsterdam is running PREVAIL (event-driven, global outcomes trial) to support U.S. approval; Europe may accept LDL-lowering data without outcomes.
Discordance among LDL-C, LDL-P, and apoB may matter uniquely for CETP inhibitors.
They highlight biomarker discordance under CETP inhibition: LDL-C and LDL-P drop substantially while apoB appears to drop less than expected, raising questions about which marker best predicts outcomes for this mechanism. Davidson emphasizes non-HDL-C and LDL-P as practical complements while noting ongoing work to determine which biomarker tracks clinical risk best when discordant.
WORDS WORTH SAVING
5 quotesSo I explain the primordial prevention concept, which is, you know, basically you wanna stop plaque from forming before it's there. And it's a lot easier to stop it from forming than it is to reversing it when it already exists.
— Michael Davidson
I like is the, um, the eight gram rule, which is that eight grams of cholesterol in your lifetime lead to heart disease.
— Michael Davidson
We don't wait for stroke and heart failure to treat hypertension. We don't wait for blindness and kidney disease to treat diabetes. So I don't know why LDL gets this like stepchild type of role when it comes to how we manage, but it is causal and we know that.
— Michael Davidson
If you lower LDL before you have a heart attack, it's very effective. If you have a heart attack and you lower LDL, it still has benefit. But once you have heart failure, there's no benefit to lowering LDL.
— Michael Davidson
Alzheimer's is not a disease of old age. It's a disease of middle age that presents in old age.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
